Walter Moos, PhD

Title(s)Professor, Pharmaceutical Chemistry
SchoolSchool of Pharmacy
Address600 16th Street, #S512B
San Francisco CA 94158
ORCID ORCID Icon0000-0001-7244-811X Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Harvard University, Cambridge, MAA.B.1976Chemistry
    University of California, Berkeley, CAPh.D.1982Chemistry
    Collapse Awards and Honors
    American Association for the Advancement of Science2020  - 2020AAAS Fellow for distinguished contributions to pharmaceutical sciences and medicinal chemistry
    University of California, San Francisco2019  - 2019Dean's Award for Outstanding Teaching
    University of Pennsylvania, Dental Medicine2019  - 2019Joseph L. Rabinowitz Memorial Lecturer
    California Polytechnic State University, San Luis Obispo2010  - 2010Baker Forum Lecturer
    American Chemical Society1991  - 1991Award for Contributions and Achievements
    American Institute of Chemists1991  - 1991AIC Fellow
    Parke Davis Pharmaceutical Research Division, Warner Lambert Company1990  - 1990President's Team Vision Award
    University of California, Berkeley1979  - 1980Chevron Fellow
    University of California, Berkeley1977  - 1977Miller Institute Fellow

    Collapse Overview 
    Collapse Overview
    Walter Moos has been a Professor (adj) of Pharmaceutical Chemistry at UCSF since 1992. In parallel, he has been Managing Director of Pandect Bioventures, which he co-founded in 2018. At ShangPharma Innovation, starting in 2016 as an advisor, then as CEO, later as Chairman (emer), he led development of the group's innovation ecosystem. He is Past President of Biosciences at the independent nonprofit Stanford Research Institute (SRI International), where he spent more than a decade, until 2016. Moos also managed corporate IT Services at SRI. Earlier he was Chairman/CEO of MitoKor (Micrologics/Migenix) and a VP at Chiron (Novartis) and at Warner-Lambert/Parke-Davis (Pfizer). He and his teams have made significant contributions to all R&D phases from early-stage research on chemical and biological therapeutics and diagnostics to marketed pharmaceutical products. They have done this with the support of VCs, foundations, government agencies, big pharma, and many others. Moos has served on more than 20 business and scientific boards, public and private, non-profit and for-profit, including Alnis, Amunix (Sanofi), Anterion, Aprinoia, Axiom (Sequenom), the Biotechnology Innovation (Industry) Organization (BIO), Circle, the Critical Path Institute, Global Blood (Pfizer), Keystone Symposia, Mimotopes (Fisher/Thermo), MitoKor (Micrologics/Migenix), Oncologic (Aduro/Chinook/Novartis), Onyx (Amgen), Rigel, ShangPharma Innovation, Valitor, and the Virginia University Research Partnership. He has advised companies on several continents and served as a committee member for academic, government, and investor groups, including the US National Academy of Sciences. He has co-founded several scientific journals, co-authored or edited multiple books, and has more than 200 publications including patents. Moos has held faculty positions at several major universities and received PhD and AB degrees in chemistry from UC Berkeley and Harvard, respectively.

    Collapse ORNG Applications 
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Epilepsy: Mitochondrial connections to the 'Sacred' disease. Mitochondrion. 2023 09; 72:84-101. Moos WH, Faller DV, Glavas IP, Kanara I, Kodukula K, Pernokas J, Pernokas M, Pinkert CA, Powers WR, Sampani K, Steliou K, Vavvas DG. PMID: 37582467.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    2. Managing the Drug Discovery Process: Insights and advice for students, educators, and practitioners; 2nd edition, 682 pages. 2023. Miller S, Moos W, Munk B, Munk S, Hart C, Spellmeyer D. View Publication.
    3. Treatment and prevention of pathological mitochondrial dysfunction in retinal degeneration and in photoreceptor injury. Biochem Pharmacol. 2022 09; 203:115168. Moos WH, Faller DV, Glavas IP, Harpp DN, Kamperi N, Kanara I, Kodukula K, Mavrakis AN, Pernokas J, Pernokas M, Pinkert CA, Powers WR, Sampani K, Steliou K, Tamvakopoulos C, Vavvas DG, Zamboni RJ, Chen X. PMID: 35835206.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    4. Future of Health & Healthcare Roundtable. 2022. Moos W, Jeffrey W, Haurwitz R, Love T, Mammen M, Murphy J, Rubin A, Wu J, Witkay P. View Publication.
    5. Pathogenic mitochondrial dysfunction and metabolic abnormalities. Biochem Pharmacol. 2021 11; 193:114809. Moos WH, Faller DV, Glavas IP, Harpp DN, Kamperi N, Kanara I, Kodukula K, Mavrakis AN, Pernokas J, Pernokas M, Pinkert CA, Powers WR, Steliou K, Tamvakopoulos C, Vavvas DG, Zamboni RJ, Sampani K. PMID: 34673016.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    6. New Venture Financing. 2021. Moos W, Loren S, Wincek R, Lo de Janvry L. View Publication.
    7. Are in-person scientific conferences dead or alive? FASEB Bioadv. 2021 Jun; 3(6):420-427. Dua N, Fyrenius M, Johnson DL, Moos WH. PMID: 34124597; PMCID: PMC8171307.
      View in: PubMed   Mentions: 5  
    8. Supporting US public health experts. Nat Biotechnol. 2020; 38:1381-4. Cohen R, Francois C, Crowley J, Hastings P, King R, Love TW, Maraganore J, McMurry-Heath M, Levin J, Co-Signatories …Moos W…. . View Publication.
    9. Klotho Pathways, Myelination Disorders, Neurodegenerative Diseases, and Epigenetic Drugs. Biores Open Access. 2020; 9(1):94-105. Moos WH, Faller DV, Glavas IP, Harpp DN, Kanara I, Mavrakis AN, Pernokas J, Pernokas M, Pinkert CA, Powers WR, Sampani K, Steliou K, Vavvas DG, Zamboni RJ, Kodukula K, Chen X. PMID: 32257625; PMCID: PMC7133426.
      View in: PubMed   Mentions: 5  
    10. Chinese scientists and US leadership in the life sciences. Nat Biotechnol. 2019; 37:1261-3. Holtzman SH, Cohen R, Levin JM, Maraganore J, Signatories to the Statement … Moos WH …. View Publication.
    11. A New Approach to Treating Neurodegenerative Otologic Disorders. Biores Open Access. 2018; 7(1):107-115. Moos WH, Faller DV, Glavas IP, Harpp DN, Irwin MH, Kanara I, Pinkert CA, Powers WR, Steliou K, Vavvas DG, Kodukula K. PMID: 30069423; PMCID: PMC6069589.
      View in: PubMed   Mentions: 5  
    12. Drug Discovery: Current Trends in Medicinal Chemistry. 2018. Moos WH, Wang GX, Koltun DO, Ndubaku C, Harstad EB. View Publication.
    13. Mitochondrial Dysfunction by Drug and Environmental Toxicants, Vol. 1, Y. Will, J.A. Dykens, Eds., Chapter 19, Toward mitochondrial medicine: Challenges in rodent modeling of human mitochondrial dysfunction. 2018; 305-13. Dunn DA, Irwin MH, Moos WH, Steliou K, Pinkert CA. View Publication.
    14. Peptides 2020: A Clear Therapeutic Vision. Protein Pept Lett. 2018; 25(12):1042-1043. Angell Y, Holford M, Moos WH. PMID: 30706773.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    15. Building on Success: A Bright Future for Peptide Therapeutics. Protein Pept Lett. 2018; 25(12):1044-1050. Angell Y, Holford M, Moos WH. PMID: 30430932.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    16. What we look for: 5 pitch essentials for life science entrepreneurs. 2018. Bidegainberry J, Brockstedt D, DiLaura P, Drakas R, Hui M, Kiron R, Kodukula K, Lively S, Lutz R, Moos W, Smith I, Spellmeyer D, Tabrizi M, Tsang B, Wei A, Wild R, Xu Y, Yang C. View Publication.
    17. Epigenetic Treatment of Neurodegenerative Ophthalmic Disorders: An Eye Toward the Future. Biores Open Access. 2017; 6(1):169-181. Moos WH, Faller DV, Glavas IP, Harpp DN, Irwin MH, Kanara I, Pinkert CA, Powers WR, Steliou K, Vavvas DG, Kodukula K. PMID: 29291141; PMCID: PMC5747116.
      View in: PubMed   Mentions: 5  
    18. Gut Microbiota and Salivary Diagnostics: The Mouth Is Salivating to Tell Us Something. Biores Open Access. 2017; 6(1):123-132. Kodukula K, Faller DV, Harpp DN, Kanara I, Pernokas J, Pernokas M, Powers WR, Soukos NS, Steliou K, Moos WH. PMID: 29098118; PMCID: PMC5665491.
      View in: PubMed   Mentions: 24  
    19. Managing the Drug Discovery Process. 2016; 1-536. Miller SM, Moos WH, Munk BH, Munk SA. View Publication.
    20. Epigenetic Treatment of Persistent Viral Infections. Drug Dev Res. 2017 02; 78(1):24-36. Moos WH, Pinkert CA, Irwin MH, Faller DV, Kodukula K, Glavas IP, Steliou K. PMID: 27761936.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    21. Innovative Approaches in Drug Discovery: Ethnopharmacology, Systems Biology and Holistic Targeting, B. Patwardhan, R. Chaguturu, Eds. Foreword: Natural Products Are Dead – Long Live Natural Products!. 2016; xxv-xxviii. Kodukula K, Moos WH. View Publication.
    22. Microbiota and Neurological Disorders: A Gut Feeling. Biores Open Access. 2016; 5(1):137-45. Moos WH, Faller DV, Harpp DN, Kanara I, Pernokas J, Powers WR, Steliou K. PMID: 27274912; PMCID: PMC4892191.
      View in: PubMed   Mentions: 52  
    23. Epigenetic Treatment of Neuropsychiatric Disorders: Autism and Schizophrenia. Drug Dev Res. 2016 Mar; 77(2):53-72. Moos WH, Maneta E, Pinkert CA, Irwin MH, Hoffman ME, Faller DV, Steliou K. PMID: 26899191.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    24. Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases. Drug Dev Res. 2016 05; 77(3):109-23. Irwin MH, Moos WH, Faller DV, Steliou K, Pinkert CA. PMID: 26899010.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    25. Bioprotective carnitinoids: lipoic acid, butyrate, and mitochondria-targeting to treat radiation injury: mitochondrial drugs come of age. Drug Dev Res. 2015 Jun; 76(4):167-75. Steliou K, Faller DV, Pinkert CA, Irwin MH, Moos WH. PMID: 26109467.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    26. A tribute to David Triggle. Biochem Pharmacol. 2015 Nov 15; 98(2):360-2. Moos WH. PMID: 25931149.
      View in: PubMed   Mentions:    Fields:    
    27. Mitochondrial drugs come of age. Drug Dev Res. 2015 Mar; 76(2):57-60. Moos WH, Dykens JA. PMID: 25832003.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    28. Radiation drugs – Still a hot topic. Drug Dev Res. 2013; 75(1):1-2. Moos WH, Shankar GN. View Publication.
    29. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One. 2013; 8(4):e60579. Madrid PB, Chopra S, Manger ID, Gilfillan L, Keepers TR, Shurtleff AC, Green CE, Iyer LV, Dilks HH, Davey RA, Kolokoltsov AA, Carrion R, Patterson JL, Bavari S, Panchal RG, Warren TK, Wells JB, Moos WH, Burke RL, Tanga MJ. PMID: 23577127; PMCID: PMC3618516.
      View in: PubMed   Mentions: 125     Fields:    Translation:HumansAnimalsCells
    30. Biomarkers – An essential tie that binds the future of drugs and diagnostics. Drug Dev Res. 2013; 74(2):63-64. Perrone JB, Kodukula K, Moos WH. View Publication.
    31. Radiation drugs – a hot topic. Drug Dev Res. 2012; 73(5):229-31. Moos WH, Shankar GN. View Publication.
    32. Pairing of Polarities. The Life and Art of Sonya Rapoport. Heyday Press, Berkeley, CA, T. Cohn, Ed., On the (r)evolution of art and science and one Sonya Rapoport. 2012; 103-6. Moos WH, Miller SM, Moos SR. View Publication.
    33. Evaluation of the pKa values and ionization sequence of bumetanide using 1H and 13C NMR and UV spectroscopy. Drug Dev Res. 2011; 72(5):416-26. Song B, Galande AK, Kodukula K, Moos WH, Miller SM. View Publication.
    34. Nonprofit pharma: solutions to what ails the industry. Curr Med Chem. 2011; 18(22):3437-40. Moos WH, Kodukula K. PMID: 21728955.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    35. Nonprofits and the valley of death in drug discovery. 2010. Moos W. View Publication.
    36. Bright lights, clearly visible in the healthcare R&D tunnel, could burn out for lack of funds. Drug Dev Res. 2009; 70(7):457-60. Moos WH, Rurka JE, Miller SM. View Publication.
    37. Nonprofit organizations and pharmaceutical research and development. Drug Dev Res. 2009; 70(7):461-71. Moos WH, Mirsalis JC . View Publication.
    38. Combinatorial chemistry: oh what a decade or two can do. Mol Divers. 2009 May; 13(2):241-5. Moos WH, Hurt CR, Morales GA. PMID: 19255865.
      View in: PubMed   Mentions: 8     Fields:    
    39. Review of the effects of 17alpha-estradiol in humans: A less feminizing estrogen with neuroprotective potential. Drug Dev Res. 2009; 70(1):1-21. Moos WH, Dykens JA, Nohynek D, Rubinchik E, Howell N. View Publication.
    40. 17alpha-estradiol: A less-feminizing estrogen. Drug Dev Res. 2008; 69(4):177-84. Moos WH, Dykens JA, Howell N. View Publication.
    41. High-Throughput Lead Optimization in Drug Discovery, T. Kshirsagar, Ed., Chapter 6, Rapid lead identification of inhibitors of adenine nucleotide translocase: A case study of applying combinatorial chemistry techniques in drug discovery. 2008; 165-76. Pei Y, Moos WH, Ghosh S. View Publication.
    42. Comprehensive Medicinal Chemistry II, Taylor JB, Triggle DJ, Eds., Vol. 2, Chapters 2.01-2.27, Strategy and Drug Research. 2007; 1-1087. Moos WH. View Publication.
    43. Nanobiotechnology: It’s a small world after all. Drug Dev Res. 2006; 67:1-3. Moos WH, Barry S. View Publication.
    44. Development of 17alpha-estradiol as a neuroprotective therapeutic agent: rationale and results from a phase I clinical study. Ann N Y Acad Sci. 2005 Jun; 1052:116-35. Dykens JA, Moos WH, Howell N. PMID: 16024755.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimalsCells
    45. Ethical issues in the biotechnology and pharmaceutical industries. Drug Dev Res. 2005; 63:89-92. Aronson D, Best SG, Werner MJ, Moos WH. View Publication.
    46. Estrogens and neuroprotection: Desperate housewives, lost, and survivor. Drug Dev Res. 2005; 66:51-2. Howell N, Dykens J, Moos WH. View Publication.
    47. Alzheimer’s disease, estrogens, and clinical trials: A case study in drug development for complex disorders. Drug Dev Res. 2005; 66:53-77. Howell N, Dykens J, Moos WH. View Publication.
    48. Efficient syntheses of benzothiazepines as antagonists for the mitochondrial sodium-calcium exchanger: potential therapeutics for type II diabetes. J Org Chem. 2003 Jan 10; 68(1):92-103. Pei Y, Lilly MJ, Owen DJ, D'Souza LJ, Tang XQ, Yu J, Nazarbaghi R, Hunter A, Anderson CM, Glasco S, Ede NJ, James IW, Maitra U, Chandrasekaran S, Moos WH, Ghosh SS. PMID: 12515466.
      View in: PubMed   Mentions: 8     Fields:    Translation:AnimalsCells
    49. Design and combinatorial synthesis of N-acyl iminodiacetic acids as bongkrekic acid analogues for the inhibition of adenine nucleotide translocase. Synthesis. 2003; 1717-21. Pei Y, Carroll AK, Anderson CM, Moos WH, Ghosh SS. View Publication.
    50. Defining the mandate of proteomics in the post-genomics era: workshop report. Mol Cell Proteomics. 2002 Oct; 1(10):763-80. Kenyon GL, DeMarini DM, Fuchs E, Galas DJ, Kirsch JF, Leyh TS, Moos WH, Petsko GA, Ringe D, Rubin GM, Sheahan LC, National Research Council Steering Committee. PMID: 12438560.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    51. The biotechnology industry in a period of opportunity and uncertainty. Drug Dev Res. 2002; 57:45-50. Moos WH, Feldbaum CB. View Publication.
    52. Cell death as a life force. Drug Dev Res. 2001; 52(4):505-507. Tomaselli KJ, Moos WH. View Publication.
    53. Combinatorial discovery process yields antimicrobial peptoids. Bioorg Med Chem. 1999 Sep; 7(9):1781-5. Ng S, Goodson B, Ehrhardt A, Moos WH, Siani M, Winter J. PMID: 10530925.
      View in: PubMed   Mentions: 12     Fields:    Translation:Cells
    54. Characterization of novel antimicrobial peptoids. Antimicrob Agents Chemother. 1999 Jun; 43(6):1429-34. Goodson B, Ehrhardt A, Ng S, Nuss J, Johnson K, Giedlin M, Yamamoto R, Moos WH, Krebber A, Ladner M, Giacona MB, Vitt C, Winter J. PMID: 10348765; PMCID: PMC89291.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCells
    55. From genes to drugs: Better, faster, cheaper. Drug Dev Res. 1998; 41(3-4):111. Kennedy GC, Moos WH. View Publication.
    56. Design and synthesis of m1-selective muscarinic agonists: (R)-(-)-(Z)-1-Azabicyclo[2.2.1]heptan-3-one, O-(3-(3'-methoxyphenyl)-2-propynyl)oxime maleate (CI-1017), a functionally m1-selective muscarinic agonist. J Med Chem. 1998 Jul 02; 41(14):2524-36. Tecle H, Barrett SD, Lauffer DJ, Augelli-Szafran C, Brann MR, Callahan MJ, Caprathe BW, Davis RE, Doyle PD, Eubanks D, Lipiniski W, Mirzadegan T, Moos WH, Moreland DW, Nelson CB, Pavia MR, Raby C, Schwarz RD, Spencer CJ, Thomas AJ, Jaen JC. PMID: 9651157.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    57. Pharmacologic characterization of CHIR 2279, an N-substituted glycine peptoid with high-affinity binding for alpha 1-adrenoceptors. J Pharmacol Exp Ther. 1996 May; 277(2):885-99. Gibbons JA, Hancock AA, Vitt CR, Knepper S, Buckner SA, Brune ME, Milicic I, Kerwin JF, Richter LS, Taylor EW, Spear KL, Zuckermann RN, Spellmeyer DC, Braeckman RA, Moos WH. PMID: 8627571.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    58. Measuring diversity: experimental design of combinatorial libraries for drug discovery. J Med Chem. 1995 Apr 28; 38(9):1431-6. Martin EJ, Blaney JM, Siani MA, Spellmeyer DC, Wong AK, Moos WH. PMID: 7739001.
      View in: PubMed   Mentions: 44     Fields:    
    59. Z-(±)-1-azabicyclo [2.2. 1] heptan-3-one, O-(3-aryl-2-propynyl) oximes as potential m1-subtype selective muscarinic agonists. Bioorg Med Chem Lett. 1995; 5(6):631-6. Tecle H, Jaen JC, Augelli-Szafran C, Barrett SD, Caprathe BW, Lauffer DJ, Mirzadegan T, Moos WH, Moreland DW, Pavia MR, Schwarz RD, Thomas AJ, Davis RE. View Publication.
    60. Molecular diversity comes of age!. Mol Diversity. 1995; 1(1):1-3. Geysen HM, Houghten RA, Kauffman S, Lebl M, Moos WH, Pavia MR, Szostak JW. View Publication.
    61. Diagnosing the decline of major pharmaceutical research laboratories: A prescription for drug companies. Drug Dev Res. 1995; 34(3):243-59. Weisbach JA, Moos WH. View Publication.
    62. Comparison of the proteolytic susceptibilities of homologous L‐amino acid, D‐amino acid, and N‐substituted glycine peptide and peptoid oligomers. Drug Dev Res. 1995; 35(1):20-32. Miller SM, Simon RJ, Ng S, Zuckermann RN, Kerr JM, Moos WH. View Publication.
    63. Proteolytic studies of homologous peptide and N-substituted glycine peptoid oligomers. Bioorg Med Chem Lett. 1994; 4(22):2657-62. Miller SM, Simon RJ, Ng S, Zuckermann RN, Kerr JM, Moos WH. View Publication.
    64. Post-modification of peptoid side chains:[3+ 2] cycloaddition of nitrile oxides with alkenes and alkynes on the solid-phase. Tetrahedron Lett. 1994; 35(32):5825-8. Pei Y, Moos WH. View Publication.
    65. Discovery of nanomolar ligands for 7-transmembrane G-protein-coupled receptors from a diverse N-(substituted) glycine peptoid library. J Med Chem. 1994; 37(17):2678-85. Zuckermann RN, Martin EJ, Spellmeyer DC, Stauber GB, Shoemaker KR, Kerr JM, Figliozzi GM, Goff DA, Siani MA, Simon RJ, Banville SC, Brown EG, Wang L, Richter LS, Moos WH. View Publication.
    66. Using peptoid libraries [oligo N-substituted glycines] for drug discovery. Techniques in Protein Chemistry. 1994; 5:533-539. Simon RJ, Martin EJ, Miller SM, Zuckermann RN, Blaney JM, Moos WH. View Publication.
    67. Recent advances in the generation of chemical diversity libraries. Drug Dev Res. 1994; 33(2):174-88. Desai MC, Zuckermann RN, Moos WH. View Publication.
    68. Pharmaceutical applications of biotechnology: promise and reality. Curr Opin Biotechnol. 1993 Dec; 4(6):711-3. Moos WH, DiRita VJ, Oxender DL. PMID: 7764469.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    69. Recent Advances in the Generation of Molecular Diversity. Annu Rep Med Chem. 1993; 28:315-24. Moos WH, Green GD, Pavia MF. View Publication.
    70. The generation of molecular diversity. Bioorg Med Chem Lett. 1993; 3(3):387-96. Pavia MR, Sawyer TK, Moos WH. View Publication.
    71. Synthesis and SAR of bulky 1-azabicyclo[2.2.1]-3-one oximes as muscarinic receptor subtype selective agonists. Life Sci. 1993; 52(5-6):505-11. Tecle H, Lauffer DJ, Mirzadegan T, Moos WH, Moreland DW, Pavia MR, Schwarz RD, Davis RE. PMID: 8382765.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    72. Therapeutic intervention in dementia. Crit Rev Neurobiol. 1993; 7(1):41-83. Davis RE, Emmerling MR, Jaen JC, Moos WH, Spiegel K. PMID: 8096799.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    73. Cholinergic agents: effect of methyl substitution in a series of arecoline derivatives on binding to muscarinic acetylcholine receptors. J Pharm Sci. 1992 Oct; 81(10):1015-9. Moos WH, Bergmeier SC, Coughenour LL, Davis RE, Hershenson FM, Kester JA, McKee JS, Marriott JG, Schwarz RD, Tecle H, et al. PMID: 1432612.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    74. A rationale for the design and synthesis of m1 selective muscarinic agonists. Bioorg Med Chem Lett. 1992; 2(8):821-6. Tecle H, Mirzadegan T, Moos WH, Moreland DW, Pavia MR, Schwarz RD, Davis RE. View Publication.
    75. Cholinomimetics and Alzheimer's disease. Bioorg Med Chem Lett. 1992; 2(8):777-80. Jaen J, Moos WH, Johnson G. View Publication.
    76. Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5. Bioorg Med Chem Lett. 1992; 2(8):803-8. Sanders KB, Thomas AJ, Pavia MR, Davis RE, Coughenour LL, Myers SL, Fisher S, Moos WH. View Publication.
    77. Acetylcholine releasing agents as cognition activators. Chemistry and pharmacology of a series of ureas. Bioorg Med Chem Lett. 1992; 2(8):855-60. Thomas AJ, Kester JA, Butler DE, Hershenson FM, Davis RE, Marriott JG, Schwarz RD, Spencer CJ, Symons JP, Moos WH. View Publication.
    78. Efficient method for the preparation of peptoids [oligo (N-substituted glycines)] by submonomer solid-phase synthesis. J Am Chem Soc. 1992; 114(26):10646-7. Zuckermann RN, Kerr JM, Kent SBH, Moos WH. View Publication.
    79. A silica gel plate-based qualitative assay for acetylcholinesterase activity: a mass method to screen for potential inhibitors. Anal Biochem. 1991 Aug 01; 196(2):439-42. Kiely JS, Moos WH, Pavia MR, Schwarz RD, Woodard GL. PMID: 1663710.
      View in: PubMed   Mentions: 1     Fields:    
    80. Next generation tacrine. Neurobiol Aging. 1991 Mar-Apr; 12(2):185-7. Schwarz RD, Davis RE, Gracon S, Hoover T, Moos WH, Pavia MR. PMID: 2052133.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    81. Cholinergic agents: 2-oxazolidinone analogues of the acetylcholine-receptor muscarinic agonist pilocarpine. Bioorg Med Chem Lett. 1991; 1(3):147-50. Hobbs SH, Johnson SJ, Kesten SR, Pavia MR, Davis RE, Schwarz RD, Coughenour LL, Myers SL, Dudley DT, Moos WH. View Publication.
    82. Cholinergic agents: Deficits in rat hippocampal choline acetyltransferase activity and spatial working memory induced by intracerebroventricular administration of stoichiometrically prepared 1-ethyl-1-(2-hydroxyethyl) aziridinium ion (AF64A). Drug Dev Res. 1991; 23(3):253-60. Moos WH, Davis RE, Kinsora JJ, Schwarz RD, Smith ME, Spencer CJ. View Publication.
    83. Conformation of three tetrahydropyridinyl oxime cognition activators. J Crystallographic Spectroscopic Res. 1991; 21(4):419-29. Bandoli G, Dolmella A, Moos WH, Nicolini M, Ongaro A. View Publication.
    84. Benzo-fused bicyclic imides. J Org Chem. 1990; 55(2):560-4. Pavia MR, Moos WH, Hershenson FM. View Publication.
    85. Adenosine Receptor Agonists. X-Ray Crystal Structure of NECA (1-(6-Amino-9 H-Purin-9-yl)-1-Deoxy-N-Ethyl-β-D-Ribofuranuronamide). Nucleosides Nucleotides. 1989; 8(4):449-61. Moos WH, Hamilton HW, Ortwine DF, Taylor MD, McPhail AT. View Publication.
    86. Evaluation in rats of the somnogenic, pyrogenic, and central nervous system depressant effects of muramyl dipeptide. Psychopharmacology (Berl). 1989; 99(1):103-8. Meltzer LT, Serpa KA, Moos WH. PMID: 2506595.
      View in: PubMed   Mentions: 3     Fields:    Translation:Animals
    87. Cognition activators. Med Res Rev. 1988 Jul-Sep; 8(3):353-91. Moos WH, Davis RE, Schwarz RD, Gamzu ER. PMID: 3043116.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    88. Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correlation with in vivo positive inotropic activity. J Med Chem. 1987 Nov; 30(11):1955-62. Sircar I, Weishaar RE, Kobylarz D, Moos WH, Bristol JA. PMID: 2822926.
      View in: PubMed   Mentions: 2     Fields:    Translation:Animals
    89. Cardiotonic agents. 8. Selective inhibitors of adenosine 3',5'-cyclic phosphate phosphodiesterase III. Elaboration of a five-point model for positive inotropic activity. J Med Chem. 1987 Nov; 30(11):1963-72. Moos WH, Humblet CC, Sircar I, Rithner C, Weishaar RE, Bristol JA, McPhail AT. PMID: 2822927.
      View in: PubMed   Mentions: 6     Fields:    Translation:Cells
    90. N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity. J Med Chem. 1987 Oct; 30(10):1709-11. Bridges AJ, Moos WH, Szotek DL, Trivedi BK, Bristol JA, Heffner TG, Bruns RF, Downs DA. PMID: 2888894.
      View in: PubMed   Mentions: 11     Fields:    Translation:Animals
    91. Drug development for senile cognitive decline. J Med Chem. 1986 Jul; 29(7):1125-30. Hershenson FM, Moos WH. PMID: 3543357.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    92. Studies on the preparation, isolation, and reactions of adenosine Schiff bases. Nucleosides Nucleotides. 1986; 5(2):201-12. Badger EW, Szotek DS, Moos WH. View Publication.
    93. Ribose-modified adenosine analogues as adenosine receptor agonists. J Med Chem. 1986 Mar; 29(3):346-53. Taylor MD, Moos WH, Hamilton HW, Szotek DS, Patt WC, Badger EW, Bristol JA, Bruns RF, Heffner TG, Mertz TE. PMID: 3005574.
      View in: PubMed   Mentions: 9     Fields:    Translation:AnimalsCells
    94. The reaction of pyridazinones with nucleophiles. An unusual reaction with cyanide. J Heterocyclic Chem. 1986; 23(5):1515-17. Badger EW, Moos WH. View Publication.
    95. N6-cycloalkyladenosines. Potent, A1-selective adenosine agonists. J Med Chem. 1985 Oct; 28(10):1383-4. Moos WH, Szotek DS, Bruns RF. PMID: 2995663.
      View in: PubMed   Mentions: 16     Fields:    Translation:Animals
    96. Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure. J Med Chem. 1984 Sep; 27(9):1099-101. Bristol JA, Sircar I, Moos WH, Evans DB, Weishaar RE. PMID: 6471063.
      View in: PubMed   Mentions: 12     Fields:    Translation:Animals
    97. Codeine analogs. Synthesis of 4a-aryldecahydroisoquinolines containing nitrogen ring functionality and of octahydro-1H-indeno [1, 2, 3-ef] isoquinolines. A total synthesis of codeine. J Org Chem. 1983; 48(2):227-238. Moos WH, Gless RD, Rapoport H. View Publication.
    98. Codeine analogs. Synthesis of 4a-(2, 3-dimethoxyphenyl) decahydroisoquinolines and octahydro-1H-[1] benzopyrano [4, 3, 2-e, f] isoquinolines. J Org Chem. 1982; 47(10):1831-7. Moos WH, Gless RD, Rapoport H. View Publication.
    99. Codeine analogs. Synthesis of spiro [benzofuran-3 (2H) 4'-piperidines] and octahydro-1H-benzofuro [3, 2-e] isoquinolines. J Org Chem. 1981; 46(25):5064-5074. Moos WH, Gless RD, Rapoport H. View Publication.
    With one click, see people who:

    Mentor Faculty

    Run Clinical Trials

    Work in Global Health Equity

    Offer Student Projects

    See more options in the Advanced Search tab

    Walter's Networks
    Concepts (200)
    Derived automatically from this person's publications.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.